About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a company based in King Of Prussia (United States) founded in 1995 was acquired by Durata Therapeutics in December 2009.. Vicuron Pharmaceuticals operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others.
- Headquarter King Of Prussia, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
Pfizer
& 1 more
-
Employee Count
Employee Count
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Vicuron Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vicuron Pharmaceuticals
Vicuron Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Pfizer and Durata Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products for treating multiple diseases are provided.
|
Founded Year | Domain | Location | |
|
Novel antibiotics for infectious diseases are developed by the company.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vicuron Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vicuron Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vicuron Pharmaceuticals Comparisons
Competitors of Vicuron Pharmaceuticals
Vicuron Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, Freeline, Vir Biotechnology and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
AAV-based gene therapies for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Vicuron Pharmaceuticals
When was Vicuron Pharmaceuticals founded?
Vicuron Pharmaceuticals was founded in 1995.
Where is Vicuron Pharmaceuticals located?
Vicuron Pharmaceuticals is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
What does Vicuron Pharmaceuticals do?
Vicuron Pharmaceuticals (formerly known as Versicor) is focused on the development of novel anti-infectives for both hospital-based and community-acquired infections. It had two products anidulafungin for fungal infections and dalbavancin for Gram-positive infections. It was initially acquired by Pfizer in June 2005 and received marketing rights for anidulafungin with the brand name Eraxis. In December 2009, Durata Therapeutics acquired Vicuron and its other drug candidate dalbavancin, which had generated Phase 3 results in acute bacterial infections of the skin and skin structures at the time of acquisition.
Who are the top competitors of Vicuron Pharmaceuticals?
Vicuron Pharmaceuticals's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Who are Vicuron Pharmaceuticals's investors?
Vicuron Pharmaceuticals has 2 investors. Key investors include Pfizer, and Durata Therapeutics.